Cell Rep Med
oregon; portland; chiles
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the observation that PD-1 and CTLA-4 are co-expressed by tumor-infiltrating lymphocytes, an investigational PD-1 x CTLA-4 bispecific DART molecule, MGD019, is engineered to maximize checkpoint blockade in the tumor microenvironment via enhanced CTLA-4 blockade in a PD-1-binding-dependent manner.
Earle A. Chiles Research Institute
Berezhnoy, Alexey; Sumrow, Bradley J; Stahl, Kurt; Shah, Kalpana; Liu, Daorong; Li, Jonathan; Hao, Su-Shin; De Costa, Anushka; Kaul, Sanjeev; Bendell, Johanna; Cote, Gregory M; Luke, Jason J; Sanborn, Rachel E; Sharma, Manish R; Chen, Francine; Li, Hua; Diedrich, Gundo; Bonvini, Ezio; and Moore, Paul A, "Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule." (2020). Articles, Abstracts, and Reports. 4346.